Integrative Genomic and Immune Repertoire Profiling Identifies Clonal Signatures Linked to Antithyroid Drug-Induced Agranulocytosis

Yi-Hui Huang[1,2], Sheng-Kai Lai[2,3], Jun-Liang Chang[4], I-Hsuan Chiu[2], Jacob Shujui Hsu[1], Chien-Yu Chen[4], Pei-Lung Chen[1,2,3,5,6,*]

[1] Graduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan

[2] Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan

[3] Genome and Systems Biology Degree Program, Academia Sinica and National Taiwan University, Taipei, Taiwan

[4] Department of Biomechatronics Engineering, National Taiwan University, Taipei, Taiwan

[5] Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

[6] Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

*Correspondence: Pei-Lung Chen, email: paylong@ntu.edu.tw, phone: +886-2-2312-3456 #288667.

ABSTRACT

Graves' disease (GD) is the leading cause of hyperthyroidism and is often treated with antithyroid drugs (ATDs). Although ATD therapy is effective, it might cause a rare but serious adverse effect called ATD-induced agranulocytosis (TiA), which can lead to severe neutropenia and life-threatening infections. Previous studies have shown that certain human leukocyte antigen (HLA) alleles, including *HLA-B*38:02* and *HLA-DRB1*08:03* in Asian populations, have been associated with TiA susceptibility. However, the underlying mechanisms remain unclear, highlighting the need to investigate the TiA-related immune alterations to better understand its pathogenesis and mechanisms.

In this study, we investigated the immune receptor repertoire in TiA patients. Global repertoire diversity, VJ gene usage, and V-J pairing remained preserved across phenotypes and disease phases. Notably, TiA patients exhibited several upregulated complementarity-determining regions 3 (CDR3) clonotypes compared to GD patients, suggesting their role in disease progression and pathogenesis. Single-cell immune repertoire analysis revealed that TiA-associated risk CDR3 sequences were predominantly expressed on CD8+ effector memory T cells (CD8 TEM) in patients with *HLA-B*38:02*, while CD4+ central memory T cells (TCM) showed increased expression of risk CDR3 sequences in patients with *HLA-DRB1*08:03*, suggesting distinct cellular mechanisms underlying HLA-associated TiA pathogenesis. In conclusion, this study sheds light on the adaptive immunoprofile associated with TiA development and provides insights into the adaptive immune profile of TiA and HLA-mediated disease susceptibility.

KEYWORDS

Graves' disease, antithyroid drug-induced agranulocytosis, human leukocyte antigen, immune receptor repertoire, single-cell sequencing

INTRODUCTION

Graves' disease (GD) is the leading cause of hyperthyroidism resulting from the

production of autoantibodies that stimulate the thyroid gland. The global incidence of Graves'

disease is around 0.02-0.05% per year, with a higher prevalence in females[1]. The condition is

often treated with antithyroid drugs (ATDs, also known as thionamide), such as

propylthiouracil (PTU) and methimazole (MMI). However, a rare but serious adverse effect

related to thionamide therapy is antithyroid drug-induced agranulocytosis (TiA) (defined as an

absolute granulocyte count <500 mm^3 within the first three months of ATD treatment), which

can occur in 0.2–0.5% of GD patients receiving these medications[2]. Given that TiA is a severe

condition that can lead to life-threatening infections, with an estimated mortality rate of 21%[3],

there is an urgent need to elucidate the pathogenic mechanisms by which ATD induce

agranulocytosis and to identify potential biomarkers for detection and risk prediction.

Although the underlying mechanisms of TiA remain unclear, previous studies have

indicated that TiA might be caused by two pathways: direct cellular toxicity and immune-

mediated destruction. The direct mechanism involves oxidative damage when ATDs

accumulate in neutrophils and are metabolized by myeloperoxidase or cytochrome P450 into

reactive metabolites that trigger inflammasome activation[4]. The immune-mediated pathway

involves circulating autoantibodies, including complement-dependent IgM antibodies,

targeting mature granulocytes and myeloid progenitor cells, leading to complement-mediated

opsonization and apoptosis[5, 6]. Importantly, bone marrow examination of 33 TiA patients has

revealed that granulocytopoiesis is significantly impaired in TiA patients[7]. These findings

suggest that TiA involves not only peripheral neutrophil destruction but also central

suppression of granulocytopoiesis at the bone marrow level, indicating a complex pathogenic

mechanism that combines both autoimmune and direct myelosuppressive effects.

Several drug-induced adverse effects have shown human leukocyte antigen (HLA) genetic

predisposition, including carbamazepine (CBZ)-induced severe cutaneous adverse reactions

(SCAR) (*HLA-B*15:02* and *HLA-A*31:01*)[8, 9], allopurinol-induced SCAR (*HLA-B*58:01*)[10],

and abacavir-induced hypersensitivity syndrome (*HLA-B*57:01*)[11, 12]. Similarly, TiA has also

been found to be associated with several HLA alleles (e.g., *HLA-B*38:02* and *HLA-*

DRB1*08:03 in Asian populations[13], *HLA-B*27:05* in European populations[14]). Three

complementary models have been proposed to explain HLA-linked drug adverse reactions: the

hapten hypothesis, where drugs covalently bind to proteins forming immunogenic adducts

presented by HLA molecules[15]; the pharmacologic interaction (p-i) model, proposing direct

drug-HLA or drug-TCR binding without metabolic activation[16]; and the altered-repertoire

model, where drugs alter HLA peptide-binding specificity, presenting novel self-peptides that

might trigger autoimmunity[17]. Importantly, recent immune repertoire study of *HLA-B*15:02*-

associated CBZ-induced SCAR has identified oligoclonal disease-causing TCR clonotypes,

supporting the p-i model[18]. Moreover, given the importance of HLA in shaping immune

receptors, individuals with different HLA alleles might exhibit distinct immunoprofiles and

downstream immune responses[19, 20]. Therefore, profiling the adaptive immune receptor

repertoire (AIRR) composed of T cell receptor (TCR) and B cell receptor (BCR), using high-

throughput sequencing could provide novel insights into the pathogenesis and underlying

mechanisms of HLA-related diseases.

In this study, we performed comprehensive immune repertoire profiling in Graves' disease

patients and those who developed ATD-induced agranulocytosis to elucidate the pathogenesis

and underlying mechanisms of Tia. Previous studies have reported an increased risk of TiA in

patients carrying *HLA-B*38:02* and *HLA-DRB1*08:03*, with estimated odds ratios (carriers to

non-carriers) 21.48 and 6.13, respectively[13]. Moreover, the combined presence of *HLA-*

B*38:02 and *HLA-DRB1*08:03* leads to an elevated odds ratio of 48.41[13]. Based on these

findings, patients enrolled in this study were assigned into four groups: (I) patients with only

HLA-B*38:02, (II) those possessing only *HLA-DRB1*08:03*, (III) patients harboring both risk alleles, (IV) those lacking both alleles. Each group included patients with TiA and GD, as well as Controls. Additionally, we collected longitudinal samples from the same patients at different stages, including the acute phase (at diagnosis) and the remission phase (0.5-1 year post-diagnosis). By comparing the global repertoire composition and clonotypes across different disease phenotypes (TiA, GD, and Control) and disease phases (acute and remission phases), we aimed to uncover TiA-associated alterations in immune responses. Furthermore, integration of single-cell immune repertoire sequencing with whole transcriptomic data provided insights into cell type distribution and paired TCR sequences. Overall, our immune repertoire study identified TiA-associated risk clonotypes, shedding light on the mechanisms underlying TiA onset, pathogenesis, and disease progression.

RESULTS

HLA Genotyping Validation Confirms Previously Identified Susceptibility Alleles in TiA

HLA genotyping of 65 TiA patients, 167 GD patients, and 125 controls validated significant

associations at previously identified *HLA-B*38:02* ($p = 3.49 \times 10^{-11}$) and *DRB1*08:03* ($p =$

2.00×10^{-4}) in TiA versus GD cases from our cohorts (Fig. 1B)[13, 21]. Subjects were stratified

into four groups according to their HLA risk allele status for subsequent immune repertoire

analysis: Group I carrying only *HLA-B*38:02* (B*38:02 only), Group II carrying only *HLA-*

*DRB1*08:03* (DRB1*08:03 only), Group III carrying both risk alleles (Both), and Group IV

lacking both alleles as controls (Without) (Table S1). Each group included TiA, GD, and

Control samples that were analyzed by bulk TCR and BCR repertoire sequencing, with a subset

additionally examined by single-cell TCR sequencing coupled with transcriptomic profiling

for comprehensive characterization (Fig. 1C).

A

Figure 1. Experimental design overview and HLA allele association validation.

(**A**) (1) Our study enrolled three cohorts: GD patients who developed TiA following ATD

treatment (TiA), GD patients without TiA (GD), and normal controls (Control). For TiA and GD patients, longitudinal samples were collected at two time points: the acute phase (at initial diagnosis) and the remission phase (typically 0.5-1 year post-diagnosis). (2) Peripheral blood mononuclear cells (PBMCs) from all participants were isolated and subjected to both bulk and single-cell immune repertoire sequencing. (3A) For bulk sequencing, total RNA was extracted using TRIzol and chloroform, followed by cDNA synthesis, template switching, and PCR amplification to generate sequencing libraries. (3B) For single-cell sequencing, sequencing libraries were prepared by three rounds of combinatorial cell barcoding. (4-5) Following sequencing, both datasets were integrated for comprehensive comparative analyses. Workflow was created in BioRender (https://BioRender.com). (**B**) Manhattan plot depicting the distribution of HLA allele frequencies compared between TiA and GD patients in our cohort. Two previously reported TiA-susceptibility alleles (*B*38:02* and *DRB1*08:03*) are labeled in red. (**C**) Study participants and sequencing coverage across the study cohort. The top panel indicates disease phenotype (TiA: red; GD: blue; Control: green). The second panel shows HLA genotype groups based on the presence of TiA-associated alleles (*B*38:02* only: dark orange; *DRB1*08:03* only: orange; both alleles: brown; without either allele: light brown). The bottom two panels illustrate the availability of bulk immune repertoire sequencing (Bulk-seq) and single-cell immune repertoire sequencing (SC-seq) data for each sample (yellow: data available; gray: data unavailable).

Repertoire-level Profiling Reveals Comparable Broad TCR and BCR Composition Across Disease States and Controls

We initially assessed three diversity indices of TCR and BCR repertoires to evaluate changes in diversity richness (relative D50), evenness (Shannon entropy), and clonal expansion (Simpson's dominance). The distribution of these diversity metrics for each subject was

visualized using tree maps (Fig. S1A-B). Subsequently, we compared diversity metrics across five groups: TiA patients in the acute phase (TiA-acute), TiA patients in remission (TiA-remission), GD patients in acute phase (GD-acute), GD patients in remission (GD-remission), and normal controls (Control).

For TCR repertoire, no statistically significant differences in diversity were observed among the five groups (Fig. 2A). To examine more detailed temporal dynamics within individuals, we further compared paired longitudinal samples across distinct disease phases. Paired comparisons of TCR repertoire revealed no differences between disease phases in TiA patients (Fig. 2B). For BCR repertoire, although GD patients during remission showed a significant reduction in Shannon entropy compared to normal controls, the other two diversity indices (relative D50 and Simpson dominance) showed no significant differences (Fig. 2C). Since these three indices reflect different aspects of repertoire diversity, the comprehensive evaluation using all three indices suggests that overall BCR repertoire diversity is similar across groups. Paired longitudinal analysis of BCR repertoire similarly showed no significant differences between disease phases in TiA patients (Fig. 2D). Collectively, these findings indicate that repertoire diversity does not differ significantly across disease phenotypes or disease phases.

Figure 2. Immune repertoire diversity across disease phenotypes and phases.

(**A**) Comparison of three diversity metrics (relative D50, Shannon entropy, and Simpson's dominance index) of TCR repertoire across five groups. Each bar represents the mean value, and individual data points are overlaid. Statistical significance was assessed using pairwise two-sample t-tests with Benjamini–Hochberg (BH) correction for multiple comparisons. (**B**) Paired longitudinal comparisons of TCR repertoire diversity metrics between TiA-acute and TiA-remission patients. Gray lines connect paired samples, and statistical significance was determined by Wilcoxon signed-rank test and adjusted with BH correction for multiple testing. (**C**) Comparison of three diversity metrics of BCR repertoire across five groups, as described in (A). (**D**) Paired longitudinal comparisons of BCR repertoire diversity metrics between TiA-acute and TiA-remission patients, as described in (B). Statistical significance was determined as $*p < 0.05$, $**p < 0.01$, $***p < 0.001$.

V(D)J recombination generates immune repertoire diversity through the selection and joining of variable (V), diversity (D), and joining (J) gene segments. To further investigate general immune profile patterns across disease phenotypes and phases, we analyzed the V/J gene usage in five groups. Overall, V/J gene usage pattern of both TCR and BCR appeared similar between five groups (Fig. S2, left). While certain genes showed elevated frequencies in TiA-acute and TiA-remission patients, statistical comparison revealed no significant differences in the usages of these genes between groups (Fig. S2, right). Beyond gene selection preferences, V-J gene pairing also contribute to receptor diversity. We therefore analyzed V-J pairing patterns across the five groups. Comparison of *TRAV-TRAJ* pairings revealed high overlap between GD-acute and GD-remission patients, but low similarity among other groups (Fig. S3A). For *TRBV-TRBJ*, *IGHV-IGHJ*, *IGKV-IGKJ*, and *IGLV-IGLJ*, we observed higher similarity across the five groups (cosine similarity > 0.8) (Fig. S3B-E). The elevated *TRAV-*

TRAJ frequencies in both TiA-acute and TiA-remission patients were predominantly driven by individual samples (e.g., elevated *TRAV5-TRAJ43* frequency in acute phase was attributed to iRep0036-1), suggesting individual variation rather than disease-associated patterns (Table S2). The overall low TRAV-TRAJ similarity may also be attributed to the larger potential combinatorial space (~2,050) compared to TRB (~650)[22].

In summary, repertoire-level analyses revealed no significant differences in diversity, V/J gene usage, or V-J pairing patterns between disease phenotypes and phases, indicating that overall TCR and BCR repertoire compositions are not altered by TiA onset and progression.

Validation of Clonotype-level Approach Through GD-associated Risk CDR3 Similarity to Pathogenic Antibodies

Despite analyzing repertoire-level characteristics including diversity, V/J gene usage, and V-J pairing patterns across the five groups, we observed no significant differences between groups, particularly between TiA-acute and GD-acute patients. This suggests that TiA-associated immune responses may involve subtle, clonotype-specific alterations rather than broad repertoire-wide shifts. We therefore performed clonotype-level analysis focusing on CDR3 regions, which directly determine antigen specificity. Following the concept of 'public T/BCRs'—shared immune receptor sequences that provide disease insights[18, 23]—we aimed to identify abundant common TiA-associated CDR3 clonotypes (referred to as clonotypes) that may drive TiA pathogenesis.

Given that TiA-associated antigens remain poorly understood, we validated our analytical pipeline by first identifying GD-associated clonotypes and evaluating whether these clonotypes could bind to the known GD-associated antigen, thyroid-stimulating hormone receptor (TSHR)[24]. We examined IGK clonotype frequencies and presence across GD-acute patients and normal control. Clonotypes with $p < 0.05$ (Wilcoxon rank-sum test) were classified as risk

clonotypes (Log_2 fold-changes (FC) > 0) or protective clonotypes (Log_2 FC < 0) (Fig. S4A).

To identify the most disease-specific candidates for structural analysis, we further evaluated

the incidence of risk and protective clonotypes using Fisher's exact test (Fig. S4B-C). GD-

specific clonotypes were defined as risk clonotypes with $p < 0.01$ that were absent in all control

samples (Fig. S4B), while control-specific clonotypes were defined as protective clonotypes

with $p < 0.01$ that were absent in all GD-acute samples (Fig. S4C). These disease-specific

clonotypes were selected for subsequent antibody-antigen docking.

We further performed structural modeling and docking analysis to characterize the binding

affinity of GD-associated clonotypes. GD-associated risk clonotypes (Fig. S4D) and protective

clonotypes (Fig. S4E) were first clustered based on CDR3 sequence similarity using

BLOSUM62-based hierarchical clustering (distance cutoff = 16), a widely adopted approach

in immune repertoire studies[25-27], as sequence similarity reflects similar loop conformations

and potential shared epitope recognition patterns. The structures of risk and protective

clonotypes (IGH derived from the reference structure) were then generated and docked with

TSHR using ClusPro[28-32]. For each docking model, we calculated epitope coverage relative to

the reference structure and binding energy using PRODIGY[33, 34]. Docking results revealed that

risk clonotypes demonstrated significantly higher epitope coverage compared to protective

clonotypes (Fig. S4F), indicating greater similarity to the reference binding site. Although

binding energies showed no significant difference between risk and protective clonotypes (Fig.

S4G), the risk clonotype "CQQRSSWPQTF" with optimal combined scores (high epitope

coverage and low binding energy) displayed a binding pose highly similar to the reference

autoantibody (Fig. S4H). In contrast, the protective clonotype "CQQSNTVPYTF" showed a

distinct binding pose from the reference (Fig. S4I). Overall, docking analysis revealed that risk

clonotypes identified from our repertoire analysis exhibited structural and binding

characteristics consistent with pathogenic thyroid-stimulating autoantibodies.

Clonotype-level Analysis Identifies HLA-linked TiA-associated TCR CDR3 Clonotypes

After validating our clonotype-level analytical pipeline, we applied it to identify TiA-associated risk clonotypes that are especially present in the acute phase. Previous studies have shown that diseases with genetic predisposition to HLA class I alleles are often associated with CD8+ T cell responses[18], while those associated with HLA class II alleles typically involve CD4+ T cells and B cells[35]. Since TiA risk HLA alleles include both HLA class I and class II[13], we examined risk clonotypes in both the TCR and BCR repertoire. To identify risk clonotypes specifically related to the acute phase in TiA, we compared clonotype frequencies of TCR (Fig. 3A-B) and BCR (Fig. S5) between TiA-acute and GD-acute patients. Shared immune receptor sequences across individuals are expected to be exceedingly rare because of the high diversity of the immune repertoire[36]. However, our identified TiA-associated (Table S1) risk clonotypes demonstrated sharing patterns, among TiA and TiA-acute patients, with each risk clonotype present in at least two TiA-acute patients. Detailed examination of patient frequency distributions revealed that these shared clonotypes also exhibited increased average frequencies within individual patients, rather than being driven by clonal expansion in single patients as observed in *TRAV-TRAJ* pairing patterns (Table S3). These findings indicate that the identified risk clonotypes represent not only disease-enriched clonotypes but also public clonotype patterns, further highlighting their association with TiA pathogenesis.

Given the strong evidence for HLA alleles predisposition in TiA[13] and the established mechanism whereby HLA-related drug adverse reactions are mediated by interactions between public TCRs, drugs, and HLA risk alleles[17], we sought to identify which TiA-associated TCR risk clonotypes exhibit HLA-dependent patterns. Since HLA-linked risk clonotypes show enrichment during the acute disease phase compared to remission stages[18], we evaluated the HLA group of TiA-acute patients expressing TiA-associated TCR risk clonotypes identified in

Fig. 3A. For TRA, four risk clonotypes (CAVRGLMDSSYKLIF, CVADTGRRALT, CVGDTGRRALTF, CVVDTGTASKLTF) showed *HLA-B*38:02* preference; two risk clonotypes (CAVRDYGGATNKLIF, CAVRSGGYNKLIF) demonstrated *HLA-DRB1*08:03*-favored patterns; and two risk clonotypes (CAFNDYKLSF, CLVGDNTGGFKTIF) showed association with both *HLA-B*38:02* and *HLA-DRB1*08:03* alleles (Fig. 3C). For TRB, five risk clonotypes (CASSFIAGANVLTF, CASSLSQGTEAFF, CASSQDLVSTDTQYF, CASSRDTNYGYTF, CASSSRTSGSYNEQFF) showed association with *HLA-B*38:02*; one risk clonotype (CASSLVGGSSYEQYF) showed *HLA-DRB1*08:03* preference; two clonotypes (CASSPGETQYF, CASSRGLAGVNEQFF) linked to both *HLA-B*38:02* and *HLA-DRB1*08:03* alleles (Fig. 3D). Position weight matrix analysis revealed distinct CDR3 sequence motifs for *B*38:02*-linked and *DRB1*08:03*-linked clonotypes in both TRA (Fig. 3E) and TRB repertoires (Fig. 3F).

Overall, these findings establish the existence of HLA-specific clonotype signatures among TiA-associated risk clonotypes identified in Fig. 3A-B, providing evidence that TiA pathogenesis involves HLA-TCR interactions mediated by antithyroid drugs. These HLA-linked clonotype signatures represent potential mechanistic biomarkers connecting genetic predisposition with adaptive immune responses in antithyroid drug-induced agranulocytosis.

Figure 3. Identification of TiA-associated TCR risk clonotypes and HLA-linked CDR3 patterns.

(**A-B**) Volcano plots showing CDR3 clonotypes of TRA (A) and TRB (B) with Log_2 FC versus $-Log_{10}$ (p-value) in TiA-acute patients compared to GD-acute subjects. Statistical significance was calculated using Wilcoxon rank-sum test. Red dots indicate significant risk clonotypes ($p < 0.05$ and Log_2 FC > 0); blue dots indicate significant protective clonotypes ($p < 0.05$ and Log_2 FC < 0); and gray dots represent non-significant clonotypes. CDR3 sequences of the most significant clonotypes are labeled. (**C-D**) The distribution of HLA-linked TRA (C) and TRB (D) CDR3 clonotypes in different HLA groups (*B*38:02* only and *DRB1*08:03* only). (**E-F**) Position weight matrices (PWM) of CDR3 sequences for TRA (E) and TRB (F) clonotypes linked to *HLA-B*38:02* (upper) and *HLA-DRB1*08:03* (lower). Each PWM depicts the V gene (left) and J gene (right) usage frequencies, with CDR3 amino acid sequences (middle). Amino acids are colored by chemical properties: acidic (red), basic (blue), hydrophobic (black), neutral (purple), and polar (green).

Integration of Single-cell Immune Repertoire Uncovers HLA-specific Cellular Distribution of TiA-associated Risk TCR Clonotypes

To gain deeper insights into TiA-associated risk TCR clonotypes, we integrated single-cell TCR repertoire data with whole transcriptomic profiles. We clustered and visualized the overall cellular landscape using uniform manifold approximation and projection (UMAP) based on transcriptomic profiles. Initial annotation revealed the cell composition (Fig. 4A), and cells were subsequently colored according to the expressing status of TiA-associated risk clonotypes (Fig. 4B). Among cells expressing TiA-associated risk clonotypes, TCRs were detected mainly on CD8+ effector memory T cells (CD8 TEM, 34.7%), CD4+ central memory T cells (CD4 TCM, 31.1%), and naïve CD8+ T cells (CD8 Naïve, 21.6%) (Fig. 4C). Upon

filtering for cells expressing TiA-associated risk clonotypes harbored by TiA-acute patients, we observed a shift in cellular distribution. Risk clonotypes were predominantly expressed on CD8 TEM cells (45.8%), CD4 TCM (20.8%), CD8 Naïve (18.8%) (Fig. 4D). To further dissect the HLA-related patterns, we stratified these risk clonotypes based on the HLA groups in which TiA patients were identified: *B*38:02* only and *DRB1*08:03* only patients. Our analysis revealed distinct cellular preferences: risk clonotypes identified in *B*38:02*-only patients were expressed on CD8 TEM (83.3%) (Fig. 4E). In contrast, while risk clonotypes from *DRB1*08:03*-only patients remained predominantly expressed on CD8 TEM, there was a notable increase in expression on CD4 TCM (40%) compared to the overall risk clonotype distribution in Figure 4D, suggesting potential HLA class II-mediated involvement in TiA pathogenesis.

These HLA-specific cellular distribution patterns demonstrate that risk clonotypes associated with different HLA alleles are expressed on distinct T cell subsets. The predominance of CD8 TEM cells in *HLA-B*38:02* carriers and the increased CD4 TCM representation in *HLA-DRB1*08:03* carriers suggest that both HLA class I and class II pathways may contribute to TiA pathogenesis through divergent cellular mechanisms.

Figure 4. Single-cell immune profiling revealing the cellular distribution of TiA-

associated risk CDR3 sequences.

(**A-B**) UMAP visualization based on transcriptomic profiles was annotated according to cell

type (A) and risk TCR clonotype detection (B). (**C-D**) Cell type composition among all cells

expressing TiA-associated risk CDR3 clonotypes (C) and those harbored by TiA-acute patients

(D). (**E-F**) Cell type composition of risk CDR3 clonotypes identified in patients carrying *HLA-*

B*38:02 (E) and *HLA-DRB1*08:03* (F). Cell types include: intermediate B cells (B

intermediate), naïve B cells (B Naïve), naïve CD4+ T cells (CD4 Naïve), CD4+ central memory

T cells (CD4 TCM), naïve CD8+ T cells (CD8 Naïve), CD8+ effector memory T cells (CD8

TEM), double-negative T cells (dnT), gamma delta T cells (γδT), natural killer cells (NK),

proliferating natural killer cells (NK Proliferating), CD56bright natural killer cells

(NK_CD56bright).

DISCUSSION

In this study, immune repertoire profiling across five disease groups revealed no

significant differences in global repertoire composition. However, several enriched TCR and

BCR clonotypes were identified in TiA-acute patients compared to GD-acute patients, which

we refer to as TiA-associated risk clonotypes. Further analysis revealed distinct CDR3

sequence motifs associated with different HLA risk alleles. Additionally, integration of single-

cell sequencing data demonstrated that these risk clonotypes were predominantly expressed on

HLA-dependent cell types.

The high diversity of immune repertoires, created by V(D)J recombination along with

nucleotide addition and deletion, results in a theoretical diversity of 10^{18} in humans[37]. While

this might suggest minimal overlap between individuals, accumulating evidence suggests that

public T cell and B cell receptors are commonly observed among patient groups and can serve

as predictive markers for disease[23]. This indicates that patients may share CDR3 sequences

relevant to disease pathogenesis, even when present at low frequencies in peripheral blood.

This concept is reflected in our observation: while no significant differences were observed at

the repertoire-level (Fig. 2 and Figs. S1-3), several TiA-associated risk clonotypes were

successfully identified in TiA-acute patients (Fig. 3). These findings suggest that TiA-

associated risk clonotypes present at subtle enrichment are insufficient to alter overall

repertoire composition, but are detectable at the clonotype level where they may play a role in

disease pathogenesis. The identification of these public, disease-associated risk clonotypes

strengthens the biological relevance of our findings and supports the hypothesis of convergent

immune responses in TiA pathogenesis.

While the pathogenic mechanisms of TiA remain unclear, Graves' disease represents a

well-established autoimmune condition mediated by autoantibodies targeting the thyrotropin

receptor (TSHR). To validate the reliability of our clonotype-level analysis approach, we

compared the frequency of BCRs between GD-acute patients and normal controls to identify

enriched clonotypes (GD-associated risk clonotypes) and decreased clonotypes (GD-associated

protective clonotypes). Comparison of TSHR protein binding between GD-associated risk and

protective clonotypes, our results demonstrated significantly higher epitope coverage by risk

clonotypes relative to protective clonotypes (Fig. S4F). This validation supports the robustness

of our clonotype-level approach and its biological relevance to disease pathogenesis.

Our integration of bulk and single-cell sequencing data revealed that TiA-associated risk

clonotypes exhibited HLA-dependent cellular distribution patterns, with *HLA-B*38:02*-linked

clonotypes enriched mainly in CD8 TEM cells and *HLA-DRB1*08:03*-linked clonotypes in

CD4 TCM cells, suggesting that these HLA alleles may contribute to TiA pathogenesis through

separate pathways (Fig. 4). Notably, despite distinct predominant cell localization patterns,

both HLA alleles showed increased proportion of CD8 TEM cells, indicating that downstream

immune responses leading to agranulocytosis likely involve CD8 TEM participation. This observation was consistent with a previous study showing that CD8+ T cells could induce inflammatory responses in various tissues, including bone marrow, leading to inhibition of granulocytopoiesis[38]. Moreover, studies have shown that the proportions of CD4+ and CD8+ effector memory T cells are increased in both peripheral blood and bone marrow of patients with aplastic anemia[39]. Given that aplastic anemia and drug-induced agranulocytosis might share similar pathophysiological mechanisms involving immune-mediated suppression of hematopoiesis, the predominant localization of TiA-associated risk clonotypes on CD8 TEM cells suggests a biologically relevant role for these cells in disease pathogenesis.

While this study provides novel insights into HLA-associated immune signatures in TiA, several limitations highlight the need for further investigation. First, several technical and biological factors might limit comparative analyses of immune repertoire. The majority of clonotypes exhibit very low frequencies within diverse repertoires, and immune repertoires are largely individualized due to technical and biological variation, making statistical comparisons challenging[40, 41]. Additionally, as demonstrated in other drug-induced reactions, disease-relevant immune cells may be enriched at tissue sites rather than peripheral blood[18], potentially limiting our ability to capture the complete immune landscape. Furthermore, drug-induced immune responses might show less pronounced clonal expansion compared to acute infections, consistent with our repertoire-level observations. Similar to autoimmune conditions where pathogenesis involves complex immune dysregulation, patients with systemic lupus erythematosus (SLE) exhibit diverse but less clonally expanded B-cell receptor repertoires[42]. As TiA likely shares similar pathophysiological features, the subtle clonal alterations might be inherently difficult to detect through repertoire-level comparisons. Second, while our integration of single-cell and bulk sequencing data revealed HLA-dependent cellular distribution patterns that provide insights into downstream immune effector mechanisms,

critical upstream pathways remain unresolved. It remains unclear whether TiA's pathogenesis is similar to other HLA-linked drug adverse reactions that are induced by HLA-TCR interactions. Most importantly, the TCR-recognized antigens driving TiA remain unknown, limiting direct validation of TCR-antigen interactions. Lastly, the limited number of cells obtained from single-cell sequencing was insufficient for comprehensive statistical analysis. Future studies integrating larger sample sizes, increased sequencing depth, expanded single-cell datasets, and critically, identification of TiA-relevant antigens, will be essential to elucidate the complete pathogenic pathway from antigen recognition to agranulocytosis. Such mechanistic understanding would facilitate the development of predictive biomarkers and targeted therapeutic interventions for TiA.

CONCLUSION

According to our previous genome-wide association study, *HLA-B*38:02* and *HLA-DRB1*08:03* were identified as independent genetic susceptibility factors for TiA. HLA genotyping of our cohort validated this association, demonstrating significant enrichment of these risk alleles in TiA patients compared to GD subjects. At the repertoire level, immune repertoire profiling showed that global repertoire composition remained comparable between TiA and GD patients, including diversity, V/J gene usage, and V-J pairing pattern. In contrast, clonotype-level analysis uncovered several TCR and BCR risk clonotypes that were significantly enriched among TiA-acute patients, highlighting their specific roles in TiA pathogenesis. Furthermore, a subset of TCR risk clonotypes with HLA-linked patterns exhibited distinct motif patterns between *HLA-B*38:02* and *HLA-DRB1*08:03* groups. Integration of bulk and single-cell immune repertoire with transcriptome sequencing demonstrated that these TiA-associated risk clonotypes were differentially distributed across T cell subsets in an HLA-dependent manner.

Overall, our study identified TiA-related clonal signatures and provided novel insights into the immunogenetic and cellular features associated with TiA. These findings highlight the potential of these clonal signatures as predictive biomarkers for risk stratification and as therapeutic targets in TiA.

MATERIALS AND METHODS

Study Populations

The overall study population and sample selection strategy were illustrated in Figure 1.

Three cohorts designated as ViRep, iRep, and iRepC were collected from National Taiwan

University Hospital (NTUH), including patients with diagnosed Graves' disease who

developed TiA, patients with Graves' disease without TiA, and Controls. Since previous studies

have demonstrated no significant difference in TiA incidence between patients receiving PTU

and those receiving MMI[43], drug type was not considered as a stratification factor in our cohort

design. Based on the previously identified two TiA-related HLA risk alleles[13], subjects from

these cohorts with defined HLA alleles status (groups I-IV) were enrolled in this study: (I)

subjects with only *HLA-B*38:02* (abbreviated as *B*38:02* only), (II) those possessing only

HLA-DRB1*08:03 (abbreviated as *DRB1*08:03* only), (III) subjects harboring both risk alleles

(abbreviated as Both), (IV) those lacking both alleles (abbreviated as Without) (Table S1). Each

group comprised TiA patients, GD patients, and Controls. Longitudinal samples were also

obtained from selected individuals during the acute phase (at the time of initial diagnosis) and

the steady phase (typically 0.5-1 year after diagnosis). In total, 82 samples from 53 patients (8

TiA, 21 GD, and 24 healthy controls) were included in immune repertoire sequencing.

HLA Genotyping

HLA genotyping was performed on five cohorts including the three cohorts mentioned

above and additional GD and VTIA cohorts, totaling 65 TiA patients, 167 GD patients, and 125

normal controls. Genomic DNA from these samples was subjected to library preparation, probe

capture-based enrichment, and sequencing as previously described[21].

Bulk Immune Repertoire Sequencing

The overall experimental workflow was illustrated in Figure 1A. RNA from PBMCs of

participants were extracted using 1ml TRIzol reagents (Invitrogen, Carlsbad, USA), followed

by preparation of cDNA libraries using the human NEBNext Immune Sequencing Kit (New

England Biolabs, Massachusetts, USA). The library construction employed reverse

transcription (RT) with oligo (dT) primers, followed by template switching with unique

molecular identifiers (UMIs) incorporation for accurate quantification. PCR amplification was

performed using P7 index primers and BCR/TCR-specific primers targeting the constant region

(C-region primers) to capture the complete V(D)J gene segments, followed by the addition of

P5 index primers to complete the library preparation for paired-end sequencing. Additionally,

a schematic representation of the paired-end 2×300 sequencing library structure, showing the

positions and length of UMIs, template switch (TS) sequences, and C-region primers, is shown

in Figure 3. High-throughput next-generation sequencing (NGS) was performed on the

NextSeq 2000 platform (Illumina, California, USA) to sequence the V(D)J junction of immune

repertoire.

Subsequently, the computational algorithm TRUST4[44] was applied to reconstruct and

defined the rearranged CDR3 of T/BCR repertoires according to the ImMunoGeneTics

information (IMGT) database (www.imgt.org). TRUST4 output files contained CDR3

clonotypes (abbreviated as clonotypes), defined as groups of sequences sharing identical CDR3

nucleotide sequences, along with their corresponding V(D)J gene usage, CDR3 nucleotide and

amino acid sequences, and read counts, which were subjected to post-analysis.

Immune Repertoire Post-analysis

Following AIRR community guidelines, analysis typically focuses on diversity, V/J gene

usages, VJ associations, and shared CDR3 clonotype to understand immune repertoire

characteristics and underlying immune-mediated pathophysiology[45].

To improve analytical resolution and avoid the interference from rare clonotypes,

clonotypes with only one count were excluded from subsequent analyses. All CDR3 sequences

were initially categorized by different TCR (TRA/TRB) and BCR (IGH/IGK/IGL) regions.

Overall repertoire diversity was estimated through three indices: relative D50, Shannon entropy, Simpson's dominance. The relative D50, a measure of repertoire richness, was defined as:

$$\text{Relative D50} = \frac{k}{N}$$

where k denotes the minimal number of top-ranked clonotypes whose cumulative frequency exceeds 50% and N is the total number of unique clonotypes in the repertoire. Lower relative D50 values indicate repertoires dominated by fewer high-abundance clonotypes. To quantify repertoire evenness, Shannon entropy was computed as:

$$H = -\sum_{i=1}^{N} p_i ln(p_i)$$

where p_i represents the relative frequency of clonotype i and N is the total number of clonotypes. Simpson's dominance was calculated as:

$$D = \sum_{i=1}^{N} p_i^2$$

with higher value indicating greater dominance and lower diversity.

V/J gene usage frequency was calculated by dividing individual V or J gene counts by the total count within each region. Similarly, V-J pairing frequency was determined by dividing specific V-J combination counts by the total count within the corresponding region. Cosine similarity between groups was calculated using the standard cosine similarity equation, where each group was represented as a vector of mean V-J pairing frequencies across all samples within that group. Frequency of CDR3 clonotypes were evaluated by dividing counts of each unique CDR3 clonotype by the total count within the corresponding region. Statistical comparisons between different disease phenotype and phases were performed using two-sided Wilcoxon rank-sum tests and adjusted for multiple comparisons using the Benjamini-Hochberg (BH) method.

Single Immune Repertoire Sequencing with Whole Transcriptomic Profiling

To simultaneously profile the whole transcriptome and immune repertoire at single-cell resolution, we utilized the Evercode™ TCR (Parse Biosciences). Single-cell suspensions were

fixed, permeabilized, and subjected to split-pool combinatorial barcoding following the

manufacturer's standard instructions. This approach enabled the precise capture of paired TCR

α and β chain sequences along with full transcriptomic data, facilitating the comprehensive

characterization of T cell subsets and clonotype tracking within the immune microenvironment.

***In Silico* Structure Prediction and Binding Affinity Assessment of BCR Clonotypes**

The crystal structure of thyroid-stimulating hormone receptor (TSHR) bound to thyroid-

stimulating autoantibody was obtained from the Protein Data Bank (PDB accession code:

3G04)[24] and used as the reference structure. Risk and non-risk BCR sequences (IGK) were

selected from GD patients during the acute phase compared to normal control based on our

repertoire analysis. The structures of selected IGK paired with IGH derived from the reference

structure were generated using AlphaFold 3[46]. Antibody-TSHR docking was performed using

ClusPro, a widely-used protein-protein docking tool[28-32]. PyMOL (PyMOL Molecular Graphics

System, Version 3.1.4.1, Schrodinger LLC, New York, NY) was used to visualize the docking

results and evaluate epitope coverage by comparing the antibody-TSHR interface with the

reference structure. Binding energies were estimated using PRODIGY[33, 34].

Statistical Analysis

Statistical differences between the two groups are explained in the respective figure

legends. R Programming (v 4.3.1) (Johns Hopkins University, Baltimore, MD) was used for

advanced statistical data analysis and visualization.

DECLARATIONS

Ethics approval and consent to participate

The study involved human participants and was conducted in accordance with the Declaration

of Helsinki. The Research Ethics Committee of National Taiwan University Hospital gave

ethical approval for this work (Approval No. 201611020RIND). Written informed consent was

obtained from all participants.

Funding

This study was supported by grants from the National Science and Technology Council, Taiwan (111-2314-B-002-243-MY3) and National Taiwan University Hospital (114-UN0086).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

We thank to National Center for High-performance Computing (NCHC) for providing computational and storage resources.

Author's contributions

Conceptualization, C.P.L., H.Y.H., L.S.K., and J.S.H.; Methodology, H.Y.H., L.S.K., and C.I.H.; Formal analysis, H.Y.H., L.S.K., and C.J.L.; Data curation, H.Y.H., L.S.K., and C.I.H.; Resources, C.Y.C., and C.P.L.; Writing – original draft, H.Y.H., and L.S.K.; Writing – review and editing, all authors. All authors read and approved the final manuscript.

REFERENCES

(1) Smith, T.J. and L. Hegedus, *Graves' Disease.* N Engl J Med, 2016. **375**(16): p. 1552-1565.

(2) Franklyn, J.A. and K. Boelaert, *Thyrotoxicosis.* Lancet, 2012. **379**(9821): p. 1155-66.

(3) Chen, W.T. and C.C. Chi, *Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies.* Br J Clin Pharmacol, 2019. **85**(9): p. 1878-1887.

(4) Vicente, N., et al., *Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management.* Drugs R D, 2017. **17**(1): p. 91-96.

(5) Fibbe, W.E., et al., *Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells.* Br J Haematol, 1986. **64**(2): p. 363-73.

(6) Guffy, M., Goeken NE, & Burns CP, *Granulocytotoxic antibodies in a patient with propylthiouracil-induced agranulocytosis.* Archives of internal medicine, 1984. **144**(8): p. 1687-1688.

(7) Xiao F, L.C., You L, Qian W, & Wei J, *Massive plasmacytosis with severe marrow suppression induced by methimazole in Graves' disease patients: case report and literature review.* International Journal of Clinical and Experimental Medicine, 2014. **7**(10): p. 3605.

(8) Cummins, J.M., et al., *Tumour suppression: disruption of HAUSP gene stabilizes p53.* Nature, 2004. **428**(6982): p. 1 p following 486.

(9) Ozeki, T., et al., *Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population.* Hum Mol Genet, 2011. **20**(5): p. 1034-41.

(10) Hung, S.I., et al., *HLA-B* 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.* Proceedings of the National Academy of Sciences, 2005. **102**(11): p. 4134-4139.

(11) Mallal, S., et al., *Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.* Lancet, 2002. **359**(9308): p. 727-32.

(12) Mallal, S., et al., *HLA-B* 5701 screening for hypersensitivity to abacavir.* New England Journal of Medicine, 2008. **358**(6): p. 568-579.

(13)   Chen, P.L., et al., *Genetic determinants of antithyroid drug-induced agranulocytosis by*
human leukocyte antigen genotyping and genome-wide association study. Nat Commun,
2015. **6**: p. 7633.

(14)   Hallberg, P., et al., *Genetic variants associated with antithyroid drug-induced*
agranulocytosis: a genome-wide association study in a European population. The
Lancet Diabetes & Endocrinology, 2016. **4**(6): p. 507-516.

(15)   Lavergne, S.N., Park, B. K., & Naisbitt, D. J.   , *The roles of drug metabolism in the*
pathogenesis of T-cell-mediated drug hypersensitivity. Current opinion in allergy and
clinical immunology, 2008. **8**(4): p. 299-307.

(16)   Pichler, W.J., et al., *Pharmacological interaction of drugs with immune receptors: the*
pi concept. Allergology International, 2006. **55**(1): p. 17-25.

(17)   Ostrov, D.A., et al., *Drug hypersensitivity caused by alteration of the MHC-presented*
self-peptide repertoire. Proc Natl Acad Sci U S A, 2012. **109**(25): p. 9959-64.

(18)   Pan, R.Y., et al., *Identification of drug-specific public TCR driving severe cutaneous*
adverse reactions. Nat Commun, 2019. **10**(1): p. 3569.

(19)   Sharon, E., et al., *Genetic variation in MHC proteins is associated with T cell receptor*
expression biases. Nat Genet, 2016. **48**(9): p. 995-1002.

(20)   Logunova, N.N., et al., *MHC-II alleles shape the CDR3 repertoires of conventional and*
regulatory naive CD4(+) T cells. Proc Natl Acad Sci U S A, 2020. **117**(24): p. 13659-
13669.

(21)   Lai, S.K., et al., *A novel framework for human leukocyte antigen (HLA) genotyping*
using probe capture-based targeted next-generation sequencing and computational
analysis. Comput Struct Biotechnol J, 2024. **23**: p. 1562-1571.

(22)   Kitaura, K., et al., *A new high-throughput sequencing method for determining diversity*
and similarity of T cell receptor (TCR) alpha and beta repertoires and identifying
potential new invariant TCR alpha chains. BMC Immunol, 2016. **17**(1): p. 38.

(23)   Attaf, M., E. Huseby, and A.K. Sewell, *alphabeta T cell receptors as predictors of*
health and disease. Cell Mol Immunol, 2015. **12**(4): p. 391-9.

(24)   Sanders, J., et al., *Crystal structure of the TSH receptor in complex with a thyroid-*
stimulating autoantibody. Thyroid, 2007. **17**(5): p. 395-410.

(25)   Dash, P., et al., *Quantifiable predictive features define epitope-specific T cell receptor*
repertoires. Nature, 2017. **547**(7661): p. 89-93.

26. Mayer-Blackwell, K., et al., *TCR meta-clonotypes for biomarker discovery with tcrdist3 enabled identification of public, HLA-restricted clusters of SARS-CoV-2 TCRs.* Elife, 2021. **10**.

27. Zhang, H., X. Zhan, and B. Li, *GIANA allows computationally-efficient TCR clustering and multi-disease repertoire classification by isometric transformation.* Nat Commun, 2021. **12**(1): p. 4699.

28. Kozakov, D., et al., *How good is automated protein docking?* Proteins, 2013. **81**(12): p. 2159-66.

29. Kozakov, D., et al., *The ClusPro web server for protein-protein docking.* Nat Protoc, 2017. **12**(2): p. 255-278.

30. Vajda, S., et al., *New additions to the ClusPro server motivated by CAPRI.* Proteins, 2017. **85**(3): p. 435-444.

31. Desta, I.T., et al., *Performance and Its Limits in Rigid Body Protein-Protein Docking.* Structure, 2020. **28**(9): p. 1071-1081 e3.

32. Jones, G., et al., *Elucidation of protein function using computational docking and hotspot analysis by ClusPro and FTMap.* Acta Crystallogr D Struct Biol, 2022. **78**(Pt 6): p. 690-697.

33. Vangone, A. and A.M. Bonvin, *Contacts-based prediction of binding affinity in protein-protein complexes.* Elife, 2015. **4**: p. e07454.

34. Xue, L.C., et al., *PRODIGY: a web server for predicting the binding affinity of protein-protein complexes.* Bioinformatics, 2016. **32**(23): p. 3676-3678.

35. Jelcic, I., et al., *Memory B Cells Activate Brain-Homing, Autoreactive CD4(+) T Cells in Multiple Sclerosis.* Cell, 2018. **175**(1): p. 85-100 e23.

36. Tanno, H., et al., *Determinants governing T cell receptor alpha/beta-chain pairing in repertoire formation of identical twins.* Proc Natl Acad Sci U S A, 2020. **117**(1): p. 532-540.

37. Sewell, A.K., *Why must T cells be cross-reactive?* Nat Rev Immunol, 2012. **12**(9): p. 669-77.

38. Gravano, D.M., et al., *CD8(+) T cells drive autoimmune hematopoietic stem cell dysfunction and bone marrow failure.* J Autoimmun, 2016. **75**: p. 58-67.

39. Hu, X., et al., *Increased CD4+ and CD8+ effector memory T cells in patients with aplastic anemia.* Haematologica, 2009. **94**(3): p. 428-9.

40. Greiff, V., et al., *A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status.* Genome Med, 2015. **7**(1): p. 49.

41. Greiff, V., et al., *Bioinformatic and Statistical Analysis of Adaptive Immune Repertoires.* Trends Immunol, 2015. **36**(11): p. 738-749.

42. Clarke, T., et al., *Autoantibody repertoire characterization provides insight into the pathogenesis of monogenic and polygenic autoimmune diseases.* Front Immunol, 2023. **14**: p. 1106537.

43. Tajiri, J., Noguchi, S., *Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis.* Thyroid, 2004. **14**(6): p. 459-462.

44. Song, L., et al., *TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data.* Nat Methods, 2021. **18**(6): p. 627-630.

45. Marquez, S., et al., *Adaptive immune receptor repertoire (AIRR) community guide to repertoire analysis.* In Immunogenetics: *Methods and Protocols*, 2022: p. 297-316.

46. Abramson, J., et al., *Accurate structure prediction of biomolecular interactions with AlphaFold 3.* Nature, 2024. **630**(8016): p. 493-500.